Research
The research activities of the Section of Hematology include both clinical and laboratory research. Details of research interests of each faculty are noted in their individual pages.
Current areas of laboratory research programs include immunobiology of plasma cell diseases, and cellular and molecular biology of blood cell production and hematopoiesis. The research activities are funded by the National Institutes of Health.
Areas of clinical research interest include myeloma and related plasma cell disorders, coagulopathies and non-malignant hematology , sickle cell disease, and palliative care .Other faculty affiliated with the section also carry out basic and clinical research related to hematology. Research programs in hematologic malignancies are in close collaboration with colleagues in the Hematology Program at Yale Cancer Center.
In addition to the individual research programs of primary faculty members of the Section of Hematology, collaborative research projects are ongoing with faculty members of several other departments, such as Laboratory Medicine, Pathology, Immunobiology and Genetics, who have common research interests
Publications
- Newest First
- Most Cited
- Most Discussed
Showing 1 - 100 results of 2,591 publications
2024
- Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasiaWang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024 PMID: 38537061, DOI: 10.1182/bloodadvances.2024012589.
- Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscapeBoddu P, Gupta A, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer J, Chandhok N, King D, Nannya Y, Ogawa S, Lin H, Simon M, Dray E, Kupfer G, Verma A, Neugebauer K, Pillai M. Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape. Molecular Cell 2024 PMID: 38521065, DOI: 10.1016/j.molcel.2024.02.032.
- Abstract 3632: Cytokine profiles associated with ICI myocarditis using machine learning approaches identifies novel cytokines and implicated pathwaysChehayeb R, Hong D, Chen N, Martinez C, Jayakrishnan R, Guajardo A, Lin D, Im Y, Halene S, VanOudenhove J, Hwa J, Jha A, Kwan J. Abstract 3632: Cytokine profiles associated with ICI myocarditis using machine learning approaches identifies novel cytokines and implicated pathways. Cancer Research 2024, 84: 3632-3632. DOI: 10.1158/1538-7445.am2024-3632.
- Abstract 7123: Biomarker-targeted alkylator and DNA damage repair inhibitor combination for refractory and relapsed acute myeloid leukemia (AML)Bhardwaj P, Sundaram R, Baassiri A, Matthews M, VanOudenhove J, Gueble S, Halene S, Bindra R. Abstract 7123: Biomarker-targeted alkylator and DNA damage repair inhibitor combination for refractory and relapsed acute myeloid leukemia (AML). Cancer Research 2024, 84: 7123-7123. DOI: 10.1158/1538-7445.am2024-7123.
- Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan A. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review. Journal Of Oncology Pharmacy Practice 2024, 10781552241238979. PMID: 38509812, DOI: 10.1177/10781552241238979.
- Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trialsMontesinos P, Fathi A, de Botton S, Stein E, Zeidan A, Zhu Y, Prebet T, Vigil C, Bluemmert I, Yu X, DiNardo C. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials. Blood Advances 2024 PMID: 38507688, DOI: 10.1182/bloodadvances.2023011914.
- Cost-effectiveness of rapid versus in-house versus send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpuraAllen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid versus in-house versus send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024 PMID: 38502197, DOI: 10.1182/bloodadvances.2024012608.
- LimitlessGoshua G. Limitless. Journal Of General Internal Medicine 2024, 1-2. PMID: 38499721, DOI: 10.1007/s11606-024-08724-8.
- Abstract P03: Splicing factor mutations induce stress granule upregulation in myeloid malignanciesBiancon G, Busarello E, Cheng M, Baccon D, VanOudenhove J, Ciceri F, Tebaldi T, Halene S. Abstract P03: Splicing factor mutations induce stress granule upregulation in myeloid malignancies. Blood Cancer Discovery 2024, 5: p03-p03. DOI: 10.1158/2643-3249.bcdsymp24-p03.
- Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and RecruitmentButt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 1-10. PMID: 38430454, DOI: 10.1007/s13187-024-02414-z.
- Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing CountryAwidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Zyoud M, Hamadneh Y, Bawa'neh H, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan A. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO Global Oncology 2024, 10: e2300281. PMID: 38422464, PMCID: PMC10914245, DOI: 10.1200/go.23.00281.
- Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug DiscoveryChan A, Han L, Delaney C, Wang X, Mukhaleva E, Li M, Yang L, Pokharel S, Mattson N, Garcia M, Wang B, Xu X, Zhang L, Singh P, Elsayed Z, Chen R, Kuang B, Wang J, Yuan Y, Chen B, Chan L, Rosen S, Horne D, Müschen M, Chen J, Vaidehi N, Armstrong S, Su R, Chen C. Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. Science Advances 2024, 10: eadk3127. PMID: 38394203, PMCID: PMC10889360, DOI: 10.1126/sciadv.adk3127.
- Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Badar T, Nanaa A, Atallah E, Shallis R, Guilherme S, Goldberg A, Saliba A, Patel A, Bewersdorf J, DuVall A, Bradshaw D, Abaza Y, Murthy G, Palmisiano N, Zeidan A, Kota V, Litzow M. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer Journal 2024, 14: 32. PMID: 38378617, PMCID: PMC10879201, DOI: 10.1038/s41408-024-01000-2.
- Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos Perez J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 2024, 38: 762-768. PMID: 38378841, DOI: 10.1038/s41375-024-02175-0.
- Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centersAbaza Y, Winer E, Murthy S, Shallis R, Matthews A, Badar T, Geramita E, Kota V, Swaroop A, Doukas P, Bradshaw D, Helenowski I, Liu Y, Zhang H, Im A, Litzow M, Perl A, Atallah E, Altman J. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. American Journal Of Hematology 2024, 99: 606-614. PMID: 38342997, DOI: 10.1002/ajh.27231.
- Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory SettingGarg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.
- Current Opinion in HematologyHalene S. Current Opinion in Hematology. Current Opinion In Hematology 2024, 31: 39. DOI: 10.1097/moh.0000000000000799.
- 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AMLNath R, Seropian S, Gyurkocza B, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Tomlinson B. 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML. Transplantation And Cellular Therapy 2024, 30: s54-s55. DOI: 10.1016/j.jtct.2023.12.089.
- 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved OutcomesForan J, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Nagl N, Brodin P, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Seropian S. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes. Transplantation And Cellular Therapy 2024, 30: s110-s111. DOI: 10.1016/j.jtct.2023.12.174.
- Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AMLChen G, Abboud C, Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Leung E, Chen M, Natwa M, Spross J, Li K, Desai A, Wahl R, Brodin P, Pandit-Taskar N. Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML. Transplantation And Cellular Therapy 2024, 30: s114-s115. DOI: 10.1016/j.jtct.2023.12.180.
- Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust EngraftmentChoe H, Nath R, Seropian S, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Gyurkocza B. Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment. Transplantation And Cellular Therapy 2024, 30: s59-s60. DOI: 10.1016/j.jtct.2023.12.094.
- Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene VicleucelAkhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.
- Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.
- Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resourceIto S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.
- Racial differences in treatment and survival among older patients with multiple myelomaWang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.
- Perspectives of Adolescents and Young Adults With Sickle Cell Disease and Clinicians on Improving Transition Readiness With a Video Game InterventionAronson P, Nolan S, Schaeffer P, Hieftje K, Ponce K, Calhoun C. Perspectives of Adolescents and Young Adults With Sickle Cell Disease and Clinicians on Improving Transition Readiness With a Video Game Intervention. Journal Of Pediatric Hematology/Oncology 2024, 46: e147-e155. PMID: 38237001, DOI: 10.1097/mph.0000000000002810.
- Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort studyThanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.
- Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemiaHuntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.
- EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIALGarcia-Manero G, Platzbecker U, Santini V, Zeidan A, Fenaux P, Komrokji R, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Degulys A, Paolini S, Cluzeau T, Della Porta M. EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL. Leukemia Research Reports 2024, 21: 100447. DOI: 10.1016/j.lrr.2024.100447.
- Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United StatesNeparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.
2023
- Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaGerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.
- Prevalence and correlates of current cigarette smoking among transgender women in ArgentinaCartujano-Barrera F, Mejia R, Radusky P, Cardozo N, Duarte M, Fabian S, Caballero R, Zalazar V, Ramos-Pibernus A, Alpert A, Cupertino A, Frola C, Aristegui I. Prevalence and correlates of current cigarette smoking among transgender women in Argentina. Frontiers In Public Health 2023, 11: 1279969. PMID: 38115852, PMCID: PMC10728477, DOI: 10.3389/fpubh.2023.1279969.
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsBewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, Irish J, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarz R, Gore S, Kim T, Zeidan A. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals Of Hematology 2023, 103: 105-116. PMID: 38036712, DOI: 10.1007/s00277-023-05552-4.
- Abstract B115: Racial and ethnic disparities in the incidence and mortality trends of acute myeloid leukemia in the United StatesKang L, Ma X, Podoltsev N, Stempel J, Wang R. Abstract B115: Racial and ethnic disparities in the incidence and mortality trends of acute myeloid leukemia in the United States. Cancer Epidemiology Biomarkers & Prevention 2023, 32: b115-b115. DOI: 10.1158/1538-7755.disp23-b115.
- Abstract C133: Identifying sexual and gender minority colorectal cancer screening disparities via the 2020 Behavioral Risk Factor Surveillance SystemWolf F, Alpert A, Schwalb M, German D. Abstract C133: Identifying sexual and gender minority colorectal cancer screening disparities via the 2020 Behavioral Risk Factor Surveillance System. Cancer Epidemiology Biomarkers & Prevention 2023, 32: c133-c133. DOI: 10.1158/1538-7755.disp23-c133.
- Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple MyelomaBrowning S, Li A, Parker T, Bar N, Anderson T, Stevens E, Liu Y, Matthews M, VanOudenhove J, Cardone R, Sun Q, Hale R, Halene S, Kibbey R, Neparidze N. Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood 2023, 142: 4774. DOI: 10.1182/blood-2023-186401.
- Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) RegistryPine A, Butt A, Garcia-Milian R, Gu S, Restrepo V, Chock Y, Hwa J, Tormey C, Rinder H, Goshua G, Belmont H, Bertolaccini M, Branch D, Erhan D, Kello N, Knight J, Petri M, Willis R, Lee A, Sharda A. Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Blood 2023, 142: 2575. DOI: 10.1182/blood-2023-185232.
- Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 TrialShallis R, Blaha O, Halene S, Mendez L, Podoltsev N, Caldwell A, Bewersdorf J, Little R, Piekarz R, Patnaik M, Gore S, Zeidan A. Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial. Blood 2023, 142: 3252. DOI: 10.1182/blood-2023-182814.
- Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction TherapyHunter C, Cheng W, Halene S, Mendez L, Podoltsev N, Zeidan A, Barbarotta L, Shallis R. Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction Therapy. Blood 2023, 142: 589. DOI: 10.1182/blood-2023-182989.
- Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center ExperienceHamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.
- Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United StatesStempel J, Li A, Pine A, Restrepo V, Bewersdorf J, Stahl M, Podoltsev N, Mendez L, Shallis R, Rangachari D, Lee A, Michaelis L, Zeidan A. Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States. Blood 2023, 142: 2319. DOI: 10.1182/blood-2023-187163.
- The Value and Success of Live Plus Online Enduring CME/CE on Hematology/Oncology Specialists' Ability to Care for Patients with Hematologic DisordersWorst M, Friedman H, Bomba S, Whitney M, Middleton D, Mikhael E, Kadkhoda H, Zhang C, Podoltsev N. The Value and Success of Live Plus Online Enduring CME/CE on Hematology/Oncology Specialists' Ability to Care for Patients with Hematologic Disorders. Blood 2023, 142: 7282. DOI: 10.1182/blood-2023-180360.
- State‐Level Acute Myeloid Leukemia Incidence and Mortality Trends and Association with Obesity in the United StatesKang L, Ma X, Podoltsev N, Stempel J, Wang R. State‐Level Acute Myeloid Leukemia Incidence and Mortality Trends and Association with Obesity in the United States. Blood 2023, 142: 5184. DOI: 10.1182/blood-2023-186428.
- A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)Maher K, Rampal R, Bose P, Podoltsev N, Harrison C, Hong J, Wang X, Chamoun K, Mascarenhas J. A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034). Blood 2023, 142: 3209. DOI: 10.1182/blood-2023-180695.
- Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) StudyAjufo H, Derkach A, Rampal R, Famulare C, Nemirovsky D, Chervin J, Ho V, Gupta V, Viswabandya A, Deeg H, Monahan T, Jain T, Jones R, Palmer J, Gerds A, Keyzner A, Lagdameo J, Gomez-Arteaga A, Van Besien K, Podoltsev N, Puzo C, Kosuri S, Amanam I, Tamari R. Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study. Blood 2023, 142: 3181. DOI: 10.1182/blood-2023-173441.
- Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS TrialGarcia-Manero G, Platzbecker U, Santini V, Zeidan A, Fenaux P, Komrokji R, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Degulys A, Paolini S, Cluzeau T, Della Porta M. Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial. Blood 2023, 142: 193. DOI: 10.1182/blood-2023-178596.
- A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGarcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland S, Litzow M, Savoie M, Medeiros B, Sekeres M, Lin T, Uy G, Powell B, Kolitz J, Larson R, Stone R, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba H. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 2023, 38: 58-66. PMID: 37935977, DOI: 10.1038/s41375-023-02073-x.
- Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant.VanOudenhove J, Liu Y, Nelakanti R, Kim D, Busarello E, Ovalle NT, Qi Z, Mamillapalli P, Siddon A, Bai Z, Axtmayer A, Corso C, Kothari S, Foss F, Isufi I, Tebaldi T, Gowda L, Fan R, Seropian S, Halene S. Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant. BioRxiv 2023 PMID: 37961434, DOI: 10.1101/2023.10.26.564259.
- High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective studyZayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.
- Peripheral Blasts in a Patient Receiving ChemotherapyKshattry S, Parker T, Huntington S. Peripheral Blasts in a Patient Receiving Chemotherapy. JAMA 2023, 330: 1581-1582. PMID: 37801303, DOI: 10.1001/jama.2023.17117.
- Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemiaHuntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.
- Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
- When to use which molecular prognostic scoring system in the management of patients with MDS?Kewan T, Bewersdorf J, Gurnari C, Xie Z, Stahl M, Zeidan A. When to use which molecular prognostic scoring system in the management of patients with MDS? Best Practice & Research Clinical Haematology 2023, 36: 101517. PMID: 38092484, DOI: 10.1016/j.beha.2023.101517.
- Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progressionEcker V, Brandmeier L, Stumpf M, Giansanti P, Moreira A, Pfeuffer L, Fens M, Lu J, Kuster B, Engleitner T, Heidegger S, Rad R, Ringshausen I, Zenz T, Wendtner C, Müschen M, Jellusova J, Ruland J, Buchner M. Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Reports 2023, 42: 113017. PMID: 37792532, DOI: 10.1016/j.celrep.2023.113017.
- PULMONARY INVASIVE MUCORMYCOSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATIONSTEMPEL J, BAR N. PULMONARY INVASIVE MUCORMYCOSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION. CHEST Journal 2023, 164: a1049-a1050. DOI: 10.1016/j.chest.2023.07.768.
- Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid LeukemiaBewersdorf J, Zeidan A. Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. 2023, 119-128. DOI: 10.1007/978-981-99-3810-0_8.
- Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasmsBadar T, Madanat Y, Zeidan A. Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future Oncology 2023, 19: 1877-1889. PMID: 37750305, DOI: 10.2217/fon-2023-0454.
- Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblastsPlatzbecker U, Santini V, Komrokji R, Zeidan A, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal J, Lai Y, Vodala S, Rosettani B, Giuseppi A, Yucel A, Fenaux P. Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia 2023, 37: 2314-2318. PMID: 37752285, PMCID: PMC10624606, DOI: 10.1038/s41375-023-02031-7.
- Transgender People’s Experiences Sharing Information With Clinicians: A Focus Group–Based Qualitative StudyAlpert A, Mehringer J, Orta S, Hernandez T, Redwood E, Rivers L, Manzano C, Ruddick R, Adams S, Sevelius J, Belanger E, Operario D, Griggs J. Transgender People’s Experiences Sharing Information With Clinicians: A Focus Group–Based Qualitative Study. The Annals Of Family Medicine 2023, 21: 408-415. PMID: 37748898, PMCID: PMC10519763, DOI: 10.1370/afm.3010.
- ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability controlGao Y, Zimmer J, Vasic R, Liu C, Gbyli R, Zheng S, Patel A, Liu W, Qi Z, Li Y, Nelakanti R, Song Y, Biancon G, Xiao A, Slavoff S, Kibbey R, Flavell R, Simon M, Tebaldi T, Li H, Halene S. ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control. Cell Reports 2023, 42: 113163. PMID: 37742191, PMCID: PMC10636609, DOI: 10.1016/j.celrep.2023.113163.
- Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemiaHuntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.
- Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.Park J, Devlin S, Durham B, Winer E, Huntington S, von Keudell G, Vemuri S, Shukla M, Falco V, Cuello B, Gore S, Stone R, Abdel-Wahab O, Tallman M. Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia. NEJM Evidence 2023, 2: evidoa2300074. PMID: 38320179, DOI: 10.1056/evidoa2300074.
- PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphomaWartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani A, Cernilogar F, van Heijster F, Hundshammer C, Schneider H, Konstantinidis F, Gabler J, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock D, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nature Cancer 2023, 4: 1508-1525. PMID: 37723306, PMCID: PMC10597841, DOI: 10.1038/s43018-023-00635-7.
- Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaPodoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemiaCroucher P, Ridinger M, Becker P, Lin T, Silberman S, Wang E, Zeidan A. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Annals Of Hematology 2023, 102: 3049-3059. PMID: 37702821, PMCID: PMC10567832, DOI: 10.1007/s00277-023-05442-9.
- P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical studyCosta L, Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Boss I, Gaudy A, Hsu K, Godwin C, San-Miguel J, Wong S. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s52-s53. DOI: 10.1016/s2152-2650(23)01652-x.
- POSTER: MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase IIIPlatzbecker U, Santini V, Fenaux P, Sekeres M, Savona M, Madanat Y, Diez-Campelo M, Valcárcel-Ferreiras D, Illmer T, Jonášová A, Bělohlávková P, Sherman L, Berry T, Dougherty S, Shah S, Xia Q, Peng L, Sun L, Wang Y, Huang F, Ikin A, Navada S, Feller F, Komrokji R, Zeidan A. POSTER: MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s185. DOI: 10.1016/s2152-2650(23)00611-0.
- POSTER: MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3Santini V, Platzbecker U, Fenaux P, Sekeres M, Savona M, Madanat Y, Díez-Campelo M, Valcárcel-Ferreiras D, Illmer T, Jonášová A, Bělohlávková P, Sherman L, Berry T, Dougherty S, Shah S, Xia Q, Peng L, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Zeidan A, Komrokji R. POSTER: MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s186. DOI: 10.1016/s2152-2650(23)00613-4.
- MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3Santini V, Platzbecker U, Fenaux P, Sekeres M, Savona M, Madanat Y, Díez-Campelo M, Valcárcel-Ferreiras D, Illmer T, JonáŠová A, Bělohlávková P, Sherman L, Berry T, Dougherty S, Shah S, Xia Q, Peng L, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Zeidan A, Komrokji R. MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s373-s374. DOI: 10.1016/s2152-2650(23)01203-x.
- MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase IIIPlatzbecker U, Santini V, Fenaux P, Sekeres M, Savona M, Madanat Y, Diez-Campelo M, Valcárcel-Ferreiras D, Illmer T, JonáŠová A, Bělohlávková P, Sherman L, Berry T, Dougherty S, Shah S, Xia Q, Peng L, Sun L, Wang Y, Huang F, Ikin A, Navada S, Feller F, Komrokji R, Zeidan A. MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s371. DOI: 10.1016/s2152-2650(23)01198-9.
- Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolutionSantinelli E, Pascale M, Xie Z, Badar T, Stahl M, Bewersdorf J, Gurnari C, Zeidan A. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. Blood Reviews 2023, 62: 101130. PMID: 37679263, DOI: 10.1016/j.blre.2023.101130.
- Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.
- Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international expertsShallis R, Daver N, Altman J, Komrokji R, Pollyea D, Badar T, Bewersdorf J, Bhatt V, de Botton S, de la Fuente Burguera A, Carraway H, Desai P, Dillon R, Duployez N, El Chaer F, Fathi A, Freeman S, Gojo I, Grunwald M, Jonas B, Konopleva M, Lin T, Mannis G, Mascarenhas J, Michaelis L, Mims A, Montesinos P, Pozdnyakova O, Pratz K, Schuh A, Sekeres M, Smith C, Stahl M, Subklewe M, Uy G, Voso M, Walter R, Wang E, Zeidner J, Žučenka A, Zeidan A. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. The Lancet Haematology 2023, 10: e767-e776. PMID: 37572683, DOI: 10.1016/s2352-3026(23)00159-x.
- Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for PathologistsMadanat Y, Zeidan A. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists. Clinics In Laboratory Medicine 2023, 43: 685-698. PMID: 37865511, DOI: 10.1016/j.cll.2023.07.003.
- Integrative analysis of transcriptome dynamics during human craniofacial development identifies candidate disease genesYankee T, Oh S, Winchester E, Wilderman A, Robinson K, Gordon T, Rosenfeld J, VanOudenhove J, Scott D, Leslie E, Cotney J. Integrative analysis of transcriptome dynamics during human craniofacial development identifies candidate disease genes. Nature Communications 2023, 14: 4623. PMID: 37532691, PMCID: PMC10397224, DOI: 10.1038/s41467-023-40363-1.
- P745: MULTI‐CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTSBewersdorf J, Shallis R, Sharon E, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Pierkarz R, Gore S, Kim T, Zeidan A. P745: MULTI‐CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS. HemaSphere 2023, 7: e30347e2. PMCID: PMC10428733, DOI: 10.1097/01.hs9.0000969884.30347.e2.
- P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCELRasheed Y, Mirza A, Pine A, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL. HemaSphere 2023, 7: e19857ae. PMCID: PMC10430478, DOI: 10.1097/01.hs9.0000972428.19857.ae.
- P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY‐POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRYButt A, Garcia‐Milian R, Goshua G, Gu S, Hwa J, Chun H, Belmont H, Kello N, Branch D, Petri M, Knight J, Willis R, Bertolaccini M, Erkan D, Lee A, Sharda A, Pine A. P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY‐POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRY. HemaSphere 2023, 7: e160607f. PMCID: PMC10429839, DOI: 10.1097/01.hs9.0000973420.16060.7f.
- P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCELMirza A, Pine A, Hamouche R, Rasheed Y, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL. HemaSphere 2023, 7: e1847498. PMCID: PMC10430598, DOI: 10.1097/01.hs9.0000972412.18474.98.
- P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTINGGarg M, Puckett J, Kamal‐Bahl S, Raut M, Ryland K, Chakraborty S, Doshi J, Huntington S. P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING. HemaSphere 2023, 7: e7912542. PMCID: PMC10429930, DOI: 10.1097/01.hs9.0000973652.79125.42.
- P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDYWong S, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Aranzazu Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Chung A, Boss I, Gaudy A, LI S, Hsu K, Godwin C, Burgess M, San-Miguel J, Jose Costa L. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY. HemaSphere 2023, 7: e1220745. PMCID: PMC10431068, DOI: 10.1097/01.hs9.0000970436.12207.45.
- P489: PROGNOSTIC IMPACT OF “MULTI‐HIT” VERSUS “SINGLE‐HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)Badar T, Atallah E, Shallis R, Goldberg A, Nanaa A, Saliba A, Patel A, Bewersdorf J, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy S, Kota V, Zeidan A, Litzow M. P489: PROGNOSTIC IMPACT OF “MULTI‐HIT” VERSUS “SINGLE‐HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND). HemaSphere 2023, 7: e429374f. PMCID: PMC10429260, DOI: 10.1097/01.hs9.0000968864.42937.4f.
- PB2010: FIRST‐LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDYZeidan A, Butrym A, Yucel A, Deshpande G, Che M, Gu T, Xiao H, Miteva D, Nadal J, Le T, Symeonidis A. PB2010: FIRST‐LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY. HemaSphere 2023, 7: e361754a. PMCID: PMC10429827, DOI: 10.1097/01.hs9.0000974852.36175.4a.
- P732: ANALYSIS OF PATIENT‐REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTSSekeres M, Santini V, Campelo M, Komrokji R, Fenaux P, Savona M, Madanat Y, Valcárcel D, Illmer T, Jonášová A, Belohlavkova P, Regnault A, Creel K, Sengupta N, Sherman L, Berry T, Dougherty S, Shah S, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Zeidan A, Platzbecker U. P732: ANALYSIS OF PATIENT‐REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS. HemaSphere 2023, 7: e5903029. PMCID: PMC10429194, DOI: 10.1097/01.hs9.0000969832.59030.29.
- P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIESSavona M, Mccloskey J, Griffiths E, Yee K, Zeidan A, Al‐Kali A, Deeg H, Patel P, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, Dezern A, Oconnell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Dao K, Chan W, Oganesian A, Sano Y, Mirakhur B, Keer H, Garcia‐Manero G. P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES. HemaSphere 2023, 7: e1342620. PMCID: PMC10429272, DOI: 10.1097/01.hs9.0000969844.13426.20.
- P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMESZeidan A, Perepezko K, Salimi T, Washington T, Epstein R. P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES. HemaSphere 2023, 7: e7673908. PMCID: PMC10428672, DOI: 10.1097/01.hs9.0000969868.76739.08.
- PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH‐RISK MYELODYSPLASTIC SYNDROMES (MDS)Zeidan A, Mosher K, Souza S, Mirakhur B, Keer H, Taylor J. PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH‐RISK MYELODYSPLASTIC SYNDROMES (MDS). HemaSphere 2023, 7: e81919d4. PMCID: PMC10429874, DOI: 10.1097/01.hs9.0000974892.81919.d4.
- P541: REAL‐WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL‐WORLD EVIDENCE DATABASE (COTA)Zeidan A, Donoso L, Hodzic S, Owusu H, Pathak D, Zhou S, Stein E. P541: REAL‐WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL‐WORLD EVIDENCE DATABASE (COTA). HemaSphere 2023, 7: e6686875. PMCID: PMC10429358, DOI: 10.1097/01.hs9.0000969072.66868.75.
- S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)Komrokji R, Ball S, Maggioni G, Travaglino E, Ali N, Fenaux P, Platzbecker U, Santini V, Campelo M, Haferlach T, Singh A, Jain A, Aguirre L, Tinsley S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Bewersdorf J, Carraway H, Dezern A, Griffiths E, Halene S, Hasserjian R, Loghavi S, Odenike O, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Lancet J, List A, Padron E, Sallman D, Zeidan A, Della Porta M. S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS). HemaSphere 2023, 7: e616260d. PMCID: PMC10428314, DOI: 10.1097/01.hs9.0000967592.61626.0d.
- PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIAZeidan A, Fathi A, Issa G, Erba H, Mackey J, Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. HemaSphere 2023, 7: e56956b1. PMCID: PMC10430098, DOI: 10.1097/01.hs9.0000974364.56956.b1.
- S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3Platzbecker U, Santini V, Fenaux P, Sekeres M, Savona M, Madanat Y, Campelo M, Valcárcel D, Illmer T, Jonášová A, Belohlavkova P, Sherman L, Berry T, Dougherty S, Shah S, Xia Q, Peng L, Sun L, Wan Y, Huang F, Ikin A, Navada S, Komrokji R, Zeidan A. S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3. HemaSphere 2023, 7: e0568592. PMCID: PMC10428232, DOI: 10.1097/01.hs9.0000967572.05685.92.
- S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA‐NAIVE LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDYDella Porta M, Platzbecker U, Santini V, Zeidan A, Fenaux P, Komrokji R, Shortt J, Valcárcel D, Jonášová A, Dimicoli-Salazar S, Tiong I, Lin C, LI J, Zhang J, Carolina Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Shetty J, Hayati S, Vodala S, Degulys A, Paolini S, Cluzeau T, Garcia-Manero G. S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA‐NAIVE LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY. HemaSphere 2023, 7: e999540c. PMCID: PMC10428433, DOI: 10.1097/01.hs9.0000967316.99954.0c.
- S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3Santini V, Platzbecker U, Fenaux P, Sekeres M, Savona M, Madanat Y, Campelo M, Valcárcel D, Illmer T, Jonášová A, Belohlavkova P, Sherman L, Berry T, Dougherty S, Shah S, Xia Q, Peng L, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Zeidan A, Komrokji R. S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3. HemaSphere 2023, 7: e5257893. PMCID: PMC10428251, DOI: 10.1097/01.hs9.0000967568.52578.93.
- P719: RANDOMIZED PHASE 1‐2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW‐DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) PATIENTS: INTERIM SAFETY ANALYSISGarcia‐Manero G, Bachishvili K, Griffiths E, Zeidan A, Traer E, Saini L, Amin H, Mohan S, Lübbert M, Maness‐Harris L, Foran J, Selleslag D, Cirici B, Pollyea D, Sallman D, Al‐Kali A, Berdeja J, Al‐Ali H, Zhu N, Lopez P, Santillana G, Santini V, Yimer H, Cripe L, Priego V, Odenike O, Heyrman B, Valcarcel D, Vachhani P, Sano Y, Mirakhur B, Oganesian A, Keer H, Yacoub A. P719: RANDOMIZED PHASE 1‐2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW‐DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) PATIENTS: INTERIM SAFETY ANALYSIS. HemaSphere 2023, 7: e551265b. PMCID: PMC10428680, DOI: 10.1097/01.hs9.0000969780.55126.5b.
- Influence of participant and reviewer characteristics in application scores for a hematology research training programVesely S, King A, Vettese E, Heller J, Cuker A, Calhoun C, Stock W, Homer M, Fritz J, Sung L. Influence of participant and reviewer characteristics in application scores for a hematology research training program. Blood Advances 2023, 7: 4064-4071. PMID: 36939221, PMCID: PMC10388723, DOI: 10.1182/bloodadvances.2023009792.
- Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costsSquires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leukemia & Lymphoma 2023, 64: 1752-1770. PMID: 37497877, DOI: 10.1080/10428194.2023.2234525.
- Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)Butt A, Allen C, Purcell A, Ito S, Goshua G. Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP). Journal Of Clinical Medicine 2023, 12: 4887. PMID: 37568288, PMCID: PMC10420213, DOI: 10.3390/jcm12154887.
- Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR AnalysisBlue B, Brazauskas R, Chen K, Patel J, Zeidan A, Steinberg A, Ballen K, Kwok J, Rotz S, Perez M, Kelkar A, Ganguly S, Wingard J, Lad D, Sharma A, Badawy S, Lazarus H, Hashem H, Szwajcer D, Knight J, Bhatt N, Page K, Beattie S, Arai Y, Liu H, Arnold S, Freytes C, Abid M, Beitinjaneh A, Farhadfar N, Wirk B, Winestone L, Agrawal V, Preussler J, Seo S, Hashmi S, Lehmann L, Wood W, Rangarajan H, Saber W, Majhail N. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. Transplantation And Cellular Therapy 2023, 29: 709.e1-709.e11. PMID: 37482244, DOI: 10.1016/j.jtct.2023.07.013.
- Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progressVenugopal S, Shallis R, Zeidan A. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress. Expert Review Of Anticancer Therapy 2023, 23: 903-911. PMID: 37470508, DOI: 10.1080/14737140.2023.2238897.
- The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cellsBrina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D’Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff J, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nature Cancer 2023, 4: 1102-1121. PMID: 37460872, DOI: 10.1038/s43018-023-00594-z.